Proteome Sciences Share Discussion Threads

[pools2] 04/10/2024 06:58

Proteome Sciences TMT reagent sales to surge: -

"Additionally, advancements in mass spectrometry-compatible labeling techniques, such as isotope-coded affinity tags (ICAT) and tandem mass tags (TMT), have facilitated the quantitative analysis of protein expression and post-translational modifications. These technological innovations are driving the adoption of advanced protein labeling techniques in both basic research and clinical applications."

[dominiccummings] 01/10/2024 16:06

and gone away....

[peverill] 01/10/2024 14:41

Has everyone sold up???

[emigna2020] 26/9/2024 13:26

MichaelG1
Member since: 19 Mar 2003

Free

..............

Please send Micky a few coins , he is in desperate need, jobless, hapless and in need of comfort after being sacked for impropriety on public transport and shops, , his mental Maskurbatory Disease was to blame = keep him off the streets please.

[peverill] 25/9/2024 18:31

Cheers Pools ;-)

[peverill] 25/9/2024 16:18

That's not commercially available then is it you gloit.

[goatherd] 25/9/2024 15:38

Yes it is. (Research only)

[peverill] 25/9/2024 14:36

It's not available commercially.!!!!!

[canaletto] 25/9/2024 08:04

Imagine how the younger Diggle brother is feeling?

[emigna2020] 25/9/2024 07:45

hahahahahah banjaxed.

[wasjobber] 25/9/2024 07:42

That's typical, now you start lying.

The test is now available from Randox. Fact.

[barry evans] 25/9/2024 07:40

Of course, in the same way that the results were good and everyone read them wrong.

Grow up ffs.

[wasjobber] 25/9/2024 07:36

That is incorrect. It is not research in the way most people interpret, but the way Randox introduce their clinical tests to market, before full CE/UKCA registration.

[barry evans] 25/9/2024 07:32

Indeed, but the sales will be pitful on research only purchases, even a ramping clown such as yourself must realise this?

I think 'Double digit' is carrying quite a lot of weight there, as will many others, I am sure.

[wasjobber] 25/9/2024 07:27

Proteome Sciences receive double digit royalties on sales of both research and clinical use of their stroke biomarkers.

[barry evans] 25/9/2024 07:18

The Neurovascular Dysfunction Biochip gives clinicians a greater understanding of conditions involving disruption of the blood-brain barrier and associated vasculature. The biomarker panel is currently useful as a research tool for disease areas such as Epilepsy, Stroke Research, Brain Inflammation, Parkinson’s Disease, Alzheimer’s Disease, Down Syndrome, Brain Injury and Delirium.

[wasjobber] 25/9/2024 07:15

Randox release their Neurovascular Dysfunction Biochip, this includes their Stroke test.

STRONG BUY

[elpirata] 23/9/2024 10:59

TMT revenues in 2023 were £3.4m & services revenues were £1.63m upon which (£5m total) prm reported an annual loss of £2.44m

H1 TMT revenues are £1.85m & services revenues £37,000 (thirty seven thousand pounds)

Another full year £m loss & H1 2025 cash crunch incoming, dont say you werent warned

[barry evans] 23/9/2024 10:51

From the latest update:

"We believe that the biotech downturn last year bottomed out in the first half of 2024 following the significant increases in orders that we have received for TMT and proteomics services in Q2 and Q3 and that the slowdown in the market is now behind us."

[wasjobber] 23/9/2024 10:47

From recent H1 2024 report and accounts: -

"After very positive feedback and the tags available thereafter, there has been a strong resurgence in TMT orders and revenues in the second half of the year that should result in full year expectations for revenues to be considerably higher than in 2023."

STRONG BUY

[barry evans] 23/9/2024 10:29

BOL!

Naturally they said nothing of teh sort, but why let that stand in the way of another pointless ramp?

[wasjobber] 23/9/2024 10:23

The new plexDIA reagents license deal will provide a large upfront payment. Also, as PRM mentioned in their H1 report and accounts, service and TMT reagent sales have now completely rebounded and revenues will be considerably higher than in 2023.

STRONG BUY